Jane Street’s Aimmune Therapeutics AIMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-90,855
Closed -$3.13M 8519
2020
Q3
$3.13M Buy
90,855
+69,690
+329% +$1.48M ﹤0.01% 2387
2020
Q2
$354K Buy
+21,165
New +$359K ﹤0.01% 5594
2020
Q1
Sell
-29,083
Closed -$743K 6306
2019
Q4
$974K Buy
29,083
+18,116
+165% +$506K ﹤0.01% 2822
2019
Q3
$230K Buy
+10,967
New +$224K ﹤0.01% 4486
2018
Q4
Sell
-19,072
Closed -$520K 6069
2018
Q3
$520K Buy
+19,072
New +$539K ﹤0.01% 3580
2018
Q2
Sell
-16,741
Closed -$512K 5886
2018
Q1
$533K Buy
+16,741
New +$589K ﹤0.01% 3417
2015
Q4
Sell
-9,943
Closed -$252K 4634
2015
Q3
$252K Buy
+9,943
New +$232K ﹤0.01% 2959

Jane Street's AIMT Position: Q4 2020 in Review

Jane Street sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 90,855 shares — an estimated $3.13M sold.

Jane Street first reported a position in AIMT in Q3 2015 and held it in 7 quarters. The position peaked at $3.13M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Jane Street reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Jane Street sold 90,855 Aimmune Therapeutics shares in Q4 2020, an estimated $3.13M.
  • Jane Street first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 7 quarters.
  • Jane Street's Aimmune Therapeutics position peaked at $3.13M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Jane Street's 13F filing for Q4 2020, filed 17 Feb 2021.